ERBB2 and breast cancer: Interestingly, our study revealed that BCT offers a significant survival advantage over mastectomy in HER-2-enriched breast cancer, with a 15-year survival rate of 92.44% in the BCT group compared to 59.61% in the mastectomy group (p < 0.001).